Thyroid Cancer Clinical Trial
Official title:
Effect of Polyglycolic Acid Mesh (Neoveil) for Reducing Drain Amount and Chyle Leakage After Thyroid Cancer Surgery: A Prospective, Randomized Controlled Study
This study is a randomized controlled study to investigate the effect of "Polyglycolic Acid Mesh Sheet (NeoveilTM)" on the thyroid cancer surgery.
Thyroid cancer is a most common solid organ cancer in South Korea, according to 2014
statistics from Korea Central Cancer Registry.
The most important treatment of thyroid cancer is a surgery. Principle of thyroid cancer
surgery is cancer-involved thyroid gland resection and central/lateral compartment of neck
node dissection.
Part of surgical complications associated with neck lymph node dissection are seroma and
chyle leakage. Incidence of seroma and chyle leakage have been reported as 4-5% and 1-7% in
previous studies. Currently, there's no effective agents to prevent these complications.
"Polyglycolic Acid Mesh Sheet (NeoveilTM)" is a tissue strengthening repair agent which is
prevent air or fluid leakage. It's effects were proven in various surgical field - prevent
air leakage in lung surgery, reduce pancreatic fistula in pancreas surgery and so on.
However, there's no result in thyroid cancer surgery.
This study will investigate the usability of NeoveilTM in thyroid cancer surgery and have the
effect of preventing seroma and chyle leakage.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
| Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
| Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
| Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
| Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
| Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
| Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
| Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
| Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
| Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
| Active, not recruiting |
NCT03246958 -
Nivolumab Plus Ipilimumab in Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
| Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
| Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|